Melinda E. Sanders

28.1k total citations · 5 hit papers
119 papers, 13.3k citations indexed

About

Melinda E. Sanders is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Melinda E. Sanders has authored 119 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 36 papers in Cancer Research and 34 papers in Molecular Biology. Recurrent topics in Melinda E. Sanders's work include Breast Cancer Treatment Studies (22 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Advanced Breast Cancer Therapies (18 papers). Melinda E. Sanders is often cited by papers focused on Breast Cancer Treatment Studies (22 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Advanced Breast Cancer Therapies (18 papers). Melinda E. Sanders collaborates with scholars based in United States, Peru and China. Melinda E. Sanders's co-authors include Jennifer A. Pietenpol, Brian D. Lehmann, Yu Shyr, Xi Chen, Justin M. Balko, Joshua A. Bauer, A. Bapsi Chakravarthy, Ingrid A. Mayer, Giampaolo Bianchini and Luca Gianni and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Nature Communications.

In The Last Decade

Melinda E. Sanders

114 papers receiving 13.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

2011 3.9k citations Brian D. Lehmann, Joshua A. Bauer et al. profile →
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

2016 2.1k citations Justin M. Balko, Ingrid A. Mayer et al. profile →
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

2016 946 citations Brian D. Lehmann, Mónica V. Estrada et al. profile →
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

2017 479 citations Kyung‐min Lee, Jennifer M. Giltnane et al. profile →
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

2013 475 citations Neil E. Bhola, Justin M. Balko et al. profile →

Peers

Countries citing papers authored by Melinda E. Sanders

Since Specialization

Citations

This map shows the geographic impact of Melinda E. Sanders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melinda E. Sanders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melinda E. Sanders more than expected).

Fields of papers citing papers by Melinda E. Sanders

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melinda E. Sanders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melinda E. Sanders. The network helps show where Melinda E. Sanders may publish in the future.

Co-authorship network of co-authors of Melinda E. Sanders

This figure shows the co-authorship network connecting the top 25 collaborators of Melinda E. Sanders. A scholar is included among the top collaborators of Melinda E. Sanders based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melinda E. Sanders. Melinda E. Sanders is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer 2024 ·Cancer Research ·(unknown), L Herrera, Pravat Kumar Parida, Suvranil Ghosh, (unknown), (unknown), Paula I. González-Ericsson, Melinda E. Sanders, Bret C. Mobley, (unknown), Todd A. Aguilera, Yan Peng, Cheryl Lewis, Carlos L. Arteaga, Ariella B. Hanker, Angelique W. Whitehurst, James B. Lorens, Rolf A. Brekken, Anthony J. Davis, Srinivas Malladi	7
2	Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC 2024 ·Cancer Letters ·(unknown), Rebecca L. Shattuck-Brandt, Carly Bess Scalise, (unknown), Sheau‐Chiann Chen, Nabil Saleh, Paula I. González-Ericsson, (unknown), Melinda E. Sanders, Gregory D. Ayers, Chi Yan, Ann Richmond	5
3	Scar matrix drives Piezo1 mediated stromal inflammation leading to placenta accreta spectrum 2024 ·Nature Communications ·Wenqiang Du, (unknown), Yamin Liu, Junaid Afzal, Yasir Suhail, (unknown), (unknown), (unknown), (unknown), Reinaldo Figueroa, Tannin A. Schmidt, Melinda E. Sanders, Molly Brewer, Kshitiz Gupta	9
4	Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer 2023 ·JAMA Oncology ·Brian D. Lehmann, Vandana G. Abramson, Elizabeth Claire Dees, Payal D. Shah, Tarah J. Ballinger, Claudine Isaacs, Cesar A. Santa‐Maria, Hanbing An, Paula I. González-Ericsson, Melinda E. Sanders, (unknown), Richard G. Abramson, Quanhu Sheng, Chih–Yuan Hsu, Yu Shyr, Antonio C. Wolff, Jennifer A. Pietenpol	18
5	NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer 2023 ·Cancer Discovery ·Brandie C. Taylor, Xiaopeng Sun, Paula I. González-Ericsson, Violeta Sánchez, Melinda E. Sanders, (unknown), Susan R. Opalenik, Ann Hanna, (unknown), Luc Van Kaer, Henry Gómez, Claudine Isaacs, Tarah J. Ballinger, Cesar A. Santa‐Maria, Payal D. Shah, Elizabeth Claire Dees, Brian D. Lehmann, Vandana G. Abramson, Jennifer A. Pietenpol, Justin M. Balko	31
6	Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance 2023 ·Journal for ImmunoTherapy of Cancer ·Jamaal L. James, Brandie C. Taylor, Margaret L. Axelrod, Xiaopeng Sun, (unknown), Paula I. González-Ericsson, Yu Wang, Violeta Sánchez, Catherine C. Fahey, Melinda E. Sanders, Yaomin Xu, Emily Hodges, Douglas B. Johnson, Justin M. Balko	16
7	Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer 2022 ·Cancer Research Communications ·Margaret L. Axelrod, Yu Wang, Yaomin Xu, Xiaopeng Sun, Cosmin A. Bejan, Paula I. González-Ericsson, Sara Nunnery, (unknown), Joshua Donaldson, Ángel Guerrero‐Zotano, Chiara Massa, Barbara Seliger, Melinda E. Sanders, Ingrid A. Mayer, Justin M. Balko	5
8	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer 2021 ·Clinical Cancer Research ·Paula I. González-Ericsson, (unknown), Rosa I. Gallagher, Xiaopeng Sun, Margaret L. Axelrod, Quanhu Sheng, Na Luo, Henry Gómez, Violeta Sánchez, Melinda E. Sanders, Lajos Pusztai, Emanuel Petricoin, Kim Blenman, Justin M. Balko, (unknown)	54
9	MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC 2020 ·JCI Insight ·Derek A. Franklin, Joe T. Sharick, Paula I. González-Ericsson, Violeta Sánchez, Phillip T. Dean, Susan R. Opalenik, Stefano Cairo, Jean-Gabriel Judde, Michael T. Lewis, Jenny C. Chang, Melinda E. Sanders, Rebecca S. Cook, Melissa C. Skala, Jennifer Bordeaux, (unknown), Christine Vaupel, Gary Geiss, Douglas Hinerfeld, Justin M. Balko	25
10	Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations 2019 ·Molecular Cancer Research ·Brian D. Lehmann, Timothy M. Shaver, Douglas B. Johnson, Zhu Li, Paula I. González-Ericsson, Violeta Sánchez, Yu Shyr, Melinda E. Sanders, Jennifer A. Pietenpol	11
11	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer 2019 ·Clinical Cancer Research ·Brian D. Lehmann, Vandana G. Abramson, Melinda E. Sanders, Erica L. Mayer, Tufia C. Haddad, Rita Nanda, Catherine Van Poznak, Anna Maria Storniolo, Julie R. Nangia, Paula I. González-Ericsson, Violeta Sánchez, Kimberly N. Johnson, Richard G. Abramson, Sheau‐Chiann Chen, Yu Shyr, Carlos L. Arteaga, Antonio C. Wolff, Jennifer A. Pietenpol	113
12	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer 2019 ·npj Breast Cancer ·Mellissa J. Nixon, Luigi Formisano, Ingrid A. Mayer, Mónica V. Estrada, Paula I. González-Ericsson, Steven J. Isakoff, Andres Forero‐Torres, Helen Won, Melinda E. Sanders, David B. Solit, Michael F. Berger, Lewis C. Cantley, Eric P. Winer, Carlos L. Arteaga, Justin M. Balko	28
13	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer 2017 ·Cancer Research ·Valerie M. Jansen, Neil E. Bhola, Joshua A. Bauer, Luigi Formisano, Kyung‐min Lee, Katherine E. Hutchinson, Agnieszka K. Witkiewicz, Preston D. Moore, Mónica V. Estrada, Violeta Sánchez, Paula I. González-Ericsson, Melinda E. Sanders, Paula R. Pohlmann, Michael J. Pishvaian, (unknown), Teresa C. Dugger, Wenyi Wei, Erik S. Knudsen, Carlos L. Arteaga	171
14	PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses 2016 ·Clinical Cancer Research ·Jiqing Sai, Philip Owens, Sergey V. Novitskiy, Oriana E. Hawkins, Anna E. Vilgelm, Jinming Yang, Tammy Sobolik, Nicole Lavender, Andrew C. Johnson, Colt M. McClain, Gregory D. Ayers, Mark C. Kelley, Melinda E. Sanders, Ingrid A. Mayer, Harold L. Moses, Mark Boothby, Ann Richmond	89
15	Quantitative Optical Imaging of Primary Tumor Organoid Metabolism Predicts Drug Response in Breast Cancer 2014 ·Cancer Research ·Alex J. Walsh, Rebecca S. Cook, Melinda E. Sanders, Luigi Aurisicchio, Gennaro Ciliberto, Carlos L. Arteaga, Melissa C. Skala	229
16	Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer 2014 ·Cancer Research ·Neil E. Bhola, Valerie M. Jansen, Sangeeta Bafna, Jennifer M. Giltnane, Justin M. Balko, Mónica V. Estrada, Ingrid M. Meszoely, Ingrid A. Mayer, Vandana G. Abramson, Fei Ye, Melinda E. Sanders, Teresa C. Dugger, Eliezer M. Van Allen, Carlos L. Arteaga	50
17	Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer 2013 ·Clinical Cancer Research ·Jennifer B. Dennison, Jennifer R. Molina, Shreya Mitra, Ana M. González-Angulo, Justin M. Balko, María G. Kuba, Melinda E. Sanders, Joseph A. Pinto, Henry Gómez, Carlos L. Arteaga, Robert Brown, Gordon B. Mills	93
18	A Multistage Genetic Association Study Identifies Breast Cancer Risk Loci at 10q25 and 16q24 2012 ·Cancer Epidemiology Biomarkers & Prevention ·(unknown), Joan P. Breyer, Kate M. McReynolds, Kevin M. Bradley, Peggy A. Schuyler, W. Dale Plummer, (unknown), Amy Trentham‐Dietz, Polly A. Newcomb, Fritz F. Parl, Melinda E. Sanders, David L. Page, Kathleen M. Egan, William D. Dupont, Jeffrey R. Smith	10
19	A Multistage Association Study Identifies a Breast Cancer Genetic Locus at NCOA7 2011 ·Cancer Research ·(unknown), Joan P. Breyer, Kevin M. Bradley, Peggy A. Schuyler, W. Dale Plummer, (unknown), Amy Trentham‐Dietz, Polly A. Newcomb, Melinda E. Sanders, David L. Page, Fritz F. Parl, Kathleen M. Egan, William D. Dupont, Jeffrey R. Smith	14
20	Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation 2010 ·Clinical Cancer Research ·Joshua A. Bauer, A. Bapsi Chakravarthy, Jennifer M. Rosenbluth, Deming Mi, Erin H. Seeley, Nara De Matos Granja-Ingram, Maria G. Olivares, Mark C. Kelley, Ingrid A. Mayer, Ingrid M. Meszoely, Julie A. Means‐Powell, Kimberly N. Johnson, C. Jillian Tsai, Gregory D. Ayers, Melinda E. Sanders, Robert J. Schneider, Silvia C. Formenti, Richard M. Caprioli, Jennifer A. Pietenpol	142

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact